Who is a realistic candidate for this injection?

Two distinct clinical pictures account for most patients who are suitable candidates for this treatment, and they differ not just in defect severity but in what the injection is intended to achieve.

The clearer-cut group comprises patients with a focal, full-thickness cartilage lesion on the acetabulum or femoral head — typically greater than 2 cm² — where the hip joint retains reasonable space (broadly Tönnis Grade 0–1 or Kellgren–Lawrence Grade I–II). Here, the aim is structural repair: the collagen scaffold fills the defect and, over roughly three to six months, supports fibrocartilage-like tissue formation in place of what has been lost. Isolated lesions in an otherwise mechanically stable hip suit this pathway best; when concurrent femoroacetabular impingement or labral pathology is present, clinical judgement determines whether it should be addressed alongside or separately.

A second, broader group presents with more diffuse wear — Kellgren–Lawrence Grade III or IV — where ChondroFiller functions less as a focal repair agent and more as a top-down biological cushion that may ease load and reduce inflammation across a wider surface area. This is symptom management supported by biology rather than targeted tissue restoration, and the two goals should not be conflated.

Patients who are not candidates for arthroscopy, or who wish to defer surgery, represent a significant proportion referred for this outpatient injection route — it requires no theatre admission and no general anaesthetic.

Known contraindications include severe pre-existing arthritis, metabolic joint disease, and known collagen allergy. Beyond those exclusions, suitability is determined by imaging findings, defect geometry, joint-space status, and symptom profile together — no single criterion applies across the board.

How the injectable collagen scaffold works inside the joint

Once ChondroFiller is placed within the defect under ultrasound guidance, a straightforward physical change triggers the biological process. The liquid — ultrapure native Type I collagen delivered through a two-chamber syringe — meets body temperature and self-polymerises within three to five minutes, forming a stable hydrogel that fills and conforms to the lesion rather than dispersing into the surrounding joint fluid.

What happens next is the mechanism that makes this more than a cushioning injection. The process is called acellular matrix-induced chondrogenesis — meaning the collagen scaffold, without containing any cells itself, acts as a chemotactic signal that draws the patient's own progenitor cells inward from the synovial lining and subchondral bone. Those recruited cells gradually remodel the scaffold into fibrocartilage-like repair tissue over roughly three to six months as the original collagen is progressively resorbed. This supports the body's own repair processes rather than substituting a synthetic material for cartilage.

Because the treatment is entirely acellular, no tissue harvest or laboratory cell-culture step is needed beforehand — a meaningful practical difference from autologous chondrocyte implantation, which involves a prior surgical biopsy.

The contrast with two other injectable options is worth noting. Hyaluronic acid functions as a short-lived lubricant; it does not recruit cells, trigger remodelling, or persist beyond a few weeks. Permanent synthetic hydrogels such as polyacrylamide gel remain in the joint indefinitely but are biologically inert — the body cannot populate or remodel them. ChondroFiller occupies a different category: a temporary biological scaffold designed to be replaced by the patient's own tissue.

Why ultrasound guidance is essential for hip injections

The hip sits in a very different anatomical position from the knee, and that difference has direct consequences for injection safety. The anterior joint space lies 4–8 cm beneath the skin — roughly three to four times the needle travel required for a typical knee injection — and the surrounding territory is anything but forgiving. The femoral artery runs approximately 1.9 cm medial to the capsule, the femoral vein around 1.7 cm medial, and the femoral nerve roughly 2.3 cm lateral. More unpredictably, the lateral circumflex femoral artery crosses directly over the anterior capsule at a position that varies between patients and cannot be inferred from surface landmarks alone.

This anatomy is why landmark-guided technique — lining up an injection using bony surface references — carries a meaningful failure rate at the hip that it simply does not carry at shallower joints. Hoeber et al. (2016), a systematic review drawing on 120 citations, quantified this precisely: accurate intra-articular placement was achieved in only 72% of landmark-guided hip injections, compared with 100% under image guidance (p<0.0001). That is a roughly one-in-four miss rate for unguided technique — not an edge case.

For ChondroFiller specifically, precision matters beyond avoiding the neurovascular corridor. The scaffold must be placed directly onto the defect site; material that disperses into the joint cavity rather than contacting the lesion cannot polymerise in the intended location and is unlikely to support meaningful repair. Real-time ultrasound enables the clinician to visualise the needle tip continuously, map each patient's neurovascular anatomy before needle insertion, and confirm intra-articular contact with the defect before the scaffold is delivered. This is not an optional refinement — it is the standard the anatomy demands.

What the clinical evidence currently shows

The published clinical picture for ChondroFiller in the hip rests primarily on one peer-reviewed series. Perez-Carro et al. (2021, PMC8322278) followed 26 patients who received arthroscopic ChondroFiller implantation for full-thickness acetabular defects alongside concurrent femoroacetabular impingement correction, reporting a mean modified Harris Hip Score improvement of approximately 30 points and MOCART cartilage-quality scores of 70–87 at follow-up. The authors characterised these results as promising and the procedure as viable — measured language that reflects genuine clinical optimism alongside appropriate caution about a single small series.

Context matters when reading those numbers. The cohort was surgically treated under arthroscopic access, enrolled on strict criteria (Tönnis Grade 0–1 joint status, isolated lesions exceeding 2 cm²), and represents a younger, better-preserved population than many patients who present for the outpatient injection pathway. Longer-term outcome data for the hip are explicitly noted as outstanding by the original authors, and no randomised controlled trial exists for ChondroFiller in this joint. Those are real gaps, and patients considering this treatment should understand them plainly.

The broader product record provides meaningful context. Over 20,000 ChondroFiller implantations have been performed across more than ten years of CE-marked clinical use in the knee, ankle, wrist, and thumb. In knee cohorts, IKDC scores have consistently improved by approximately 30 points over twelve months — a pattern that positions the hip application within a well-evidenced product family rather than as an isolated experimental use, even though hip-specific data remain thinner.

One further evidence boundary is worth stating directly. As of mid-2026, no dedicated published outcomes series exists for the ultrasound-guided outpatient injection route in the hip specifically. The clinical rationale for this approach draws on the mechanism of action, the accuracy data for image-guided delivery, and the surgical cohort results — all of which are sound — but the injection-route data gap is an honest limitation of the current evidence base, not a flaw in the treatment concept itself.

How ChondroFiller compares to other hip injection options

Choosing between injection options for a hip cartilage problem is less about finding the best treatment in the abstract and more about matching the right mechanism to the right clinical picture.

Hyaluronic acid (viscosupplementation) works as a joint lubricant. It can reduce friction and ease symptoms in the short term but is cleared from the joint within weeks and does not initiate any cellular repair process. It is a palliative tool, not a tissue-directed one.

Arthrosamid, a polyacrylamide hydrogel, integrates into the synovial lining as a long-lasting cushion and can provide sustained symptom relief for arthritic hips. Because it is a permanent, non-biodegradable gel, its role is mechanical rather than regenerative. ChondroFiller and Arthrosamid are not interchangeable — one is a scaffold that recruits the body's own progenitor cells, the other a stable filler that does not degrade or remodel. If both were used together, they would serve genuinely different biological purposes.

Microfracture is the established surgical standard for small focal chondral lesions. It stimulates repair, but the fibrocartilage it produces is structurally different from hyaline cartilage and clinical benefit can diminish beyond two to three years. ChondroFiller's collagen scaffold provides a structured environment intended to support more organised tissue formation — though direct head-to-head hip data are not yet available to quantify any advantage.

PRP, microfragmented fat (Lipogems), and bone marrow aspirate concentrate (BMAC) act through biologic rather than scaffold pathways and may suit certain presentations better than, or alongside, a collagen scaffold approach.

The appropriate comparison ultimately depends on defect size, residual joint space, symptom pattern, and what a patient is hoping to achieve — all of which are weighed at a consultant-led assessment.

The outpatient assessment and treatment pathway

From first contact to post-injection review, the pathway at MSK Doctors is designed to be straightforward and consultant-led throughout — no GP referral is needed and there are no NHS-style waiting lists.

Assessment typically begins with a review of any existing MRI. Where imaging is absent or insufficiently detailed for defect characterisation, the team can arrange it directly. Where gait-loading patterns are clinically relevant — for example, when a biomechanical driver of abnormal joint loading is suspected — MAI Motion®, the clinic's UKCA-registered markerless motion capture system, may be used to add objective data to the clinical picture.

Once candidacy is confirmed, the injection itself is carried out as an outpatient appointment at the Sleaford or Grantham clinic. Under local anaesthesia, and with real-time ultrasound visualisation throughout, the collagen scaffold is placed directly onto the defect site. There is no theatre admission, no general anaesthetic, and no surgical incision.

Patients leave the same day with a post-injection protocol covering activity, loading, and follow-up. Realistic expectations matter here: scaffold maturation and cellular remodelling continue over three to six months, so symptom changes in the first weeks reflect only the earliest phase of tissue response rather than the full effect.

MSK Doctors holds a CQC 'Good' rating across all five inspection domains. Patients wishing to explore whether this pathway suits their hip can book a consultant assessment directly at mskdoctors.com.

1. [1] Hip Chondral Defects: Arthroscopic Treatment With the Needle and Curette Technique and ChondroFiller (Perez-Carro et al., 2021). (2021). https://pmc.ncbi.nlm.nih.gov/articles/PMC8322278/ https://pmc.ncbi.nlm.nih.gov/articles/PMC8322278/